q4 revenue rose 16.4 percent to $5.6 billion.
ex's board approved acquisition of Tavr therapy from Avid.
compname reports results for third quarter of fiscal year, sees fiscal 2021 revenues $3.0 billion to $3 bln.
q3 revenue rose 3.7 percent to $2.14 billion.
qtrly transcatheter heart valve sales rose 32 percent on a recurring basis to $432 million.
q2 sales rose 14 percent to $2.2 billion.
paraphrase:
compname announces q3 results; average selling prices held stable globally.
compname reports q2 sales of $267 million.
qtrly total revenues grew more than 20 percent to $1.46 billion.
q1 sales $1.8 billion versus refinitiv ibes estimate of $1,711.9 million.
compname announces q4 net sales of $961 million, up 19% versus q4 of fiscal 2021.
exceeds 2021 guidance of 1.2 percent revenue growth globally.
company reports full-year 2021 results.
sees total tavr procedure growth in europe was about 15% in q4 of 2021.
qtrly net sales decrease in france driven by continued impact of lower prices.
